Madrigal Pharmaceuticals, Inc. Common Stock (MDGL) Financials
Key financial figures for Madrigal Pharmaceuticals, Inc. Common Stock (Q3 2026).
Rezdiffra net sales rose 50% to $431.3 million and Madrigal posted its first profitable quarter, with net income of $55.4 million. Net revenues were $431.3 million, up 50% from $287.3 million in the year-ago quarter, driven by increased U.S. demand for Rezdiffra, Madrigal's only marketed product. The release gives no analyst estimate, so this is stated against the prior year. First profitable quarter: income from operations was $56.0 million (10-Q) versus a $114.0 million operating loss a year earlier, and net income was $55.4 million ($1.83 per diluted share) versus a net loss of $114.2 million ($4.01 per share). Operating expenses were $375.3 million versus $401.2 million. Figures are for Q3 2026, as Madrigal Pharmaceuticals Inc. reported them.
- Revenue
- $431M
- Net Income
- $55M
- EPS
- $1.90
- Total Assets
- $1.4B
- Operating Cash Flow
- $121M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q3 FY2026 | $431M | $55M | $1.83 | 12.98% | $117M |
| Q2 FY2026 | $364M | -$58M | -$1.99 | -15.46% | $19M |
| Q1 FY2026 | $311M | -$94M | -$3.25 | -29.78% | -$171M |
| Q4 FY2025 | $321M | -$59M | -$2.57 | -18.56% | |
| Q3 FY2025 | $287M | -$114M | -$5.08 | -39.68% | $79M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $958M | -$288M | -$12.85 | -31.31% | -$190M |
| FY2024 | $180M | -$466M | -$21.90 | -276.39% | -$457M |
| FY2023 | $0 | -$374M | -$17.33 | -$326M |
Frequently asked questions
What was Madrigal Pharmaceuticals Inc.'s revenue last quarter?
Madrigal Pharmaceuticals Inc. reported revenue of $431.3 million for Q3 FY2026, up 50.1% from the same period a year earlier.
Is Madrigal Pharmaceuticals Inc. profitable?
Yes. Madrigal Pharmaceuticals Inc. reported net income of $55.4 million for Q3 FY2026, a net margin of 12.86% on revenue.
How has Madrigal Pharmaceuticals Inc.'s margin trended?
Operating margin was 12.98% in Q3 FY2026, compared with -39.68% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Madrigal Pharmaceuticals Inc. generate?
Madrigal Pharmaceuticals Inc. generated free cash flow of $116.6 million in Q3 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Madrigal Pharmaceuticals, Inc. Common Stock on SentiSense, with up to forty quarters and twenty fiscal years of history.